| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*See the Appendix on page 1658 for a list of participating investigators.
From the Diamond Headache Clinic (Dr. Freitag), Chicago, IL; Abbott Laboratories (Drs. Collins and Sommerville, H.A. Carlson, and R. Deaton), Abbott Park, IL, and RW Johnson PRD (Dr. Collins); San Francisco Headache Clinic (Dr. Goldstein), CA; the Michigan Head Pain & Neurological Institute (Dr. Saper); Jefferson Headache Center (Dr. Silberstein), Philadelphia, PA; Houston Headache Clinic (Dr. Mathew), TX; and the Palm Beach Headache Clinic (Dr. Winner), FL.
Address correspondence and reprint requests to Dr. Frederick G. Freitag, Diamond Headache Clinic, 467 W. Deming Place, Chicago, IL 60614.
Objective: To evaluate the efficacy and safety of extended-release divalproex sodium compared with placebo in prophylactic monotherapy treatment of migraine headache.
Methods: This was a double-blind, randomized, placebo-controlled, parallel-group study. Subjects with more than two migraine headache attacks during a 4-week baseline were randomly assigned in a 1:1 ratio at each center to receive either extended-release divalproex sodium or matching placebo once daily for 12 weeks. Subjects initiated treatment on 500 mg once daily for 1 week, and the dose was then increased to 1,000 mg once daily with an option, if intolerance occurred, to permanently decrease the dose to 500 mg during the second week. Reduction from baseline in 4-week migraine headache rate was the primary efficacy variable. Migraine headaches separated by a <24-hour headache-free interval were counted as single migraines in calculating migraine headache rates. Tolerance and safety were also evaluated.
Results: The mean reductions in 4-week migraine headache rate were 1.2 (from a baseline mean of 4.4) in the extended-release divalproex sodium group and 0.6 (from a baseline mean of 4.2) in the placebo group (p = 0.006); reductions with extended-release divalproex sodium were significantly greater than with placebo in all three 4-week segments of the treatment period. No significant differences were detected between treatment groups in either the overall incidence or in the incidence of any specific treatment-emergent adverse event; 8% of subjects treated with extended-release divalproex sodium and 9% of those treated with placebo discontinued for adverse events.
Conclusion: Extended-release divalproex sodium is an efficacious, well-tolerated, safe, and easy-to-use once-a-day prophylactic antimigraine medication.
This article has been cited by other articles:
|
|
 |
|
  K. A. Pesaturo and F. G. Wooding Modern Management of the Migraine Headache American Journal of Lifestyle Medicine, March 1, 2009; 3(2): 147 - 159. [Abstract] [PDF]
|
|
|
|
 |
|
 D W Dodick and S D Silberstein Migraine prevention Practical Neurology, November 1, 2007; 7(6): 383 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. S Eiland, L. S Jenkins, and S. H Durham Pediatric Migraine: Pharmacologic Agents for Prophylaxis Ann. Pharmacother., July 1, 2007; 41(7): 1181 - 1190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Verrotti, C. Salladini, G. Di Marco, F. Pisciella, and F. Chiarelli Extended-Release Formulations in Epilepsy J Child Neurol, April 1, 2007; 22(4): 419 - 426. [Abstract] [PDF]
|
|
|
|
|
|
S. Dutta, R. C Reed, and R. F O'Dea Comparative Absorption Profiles of Divalproex Sodium Delayed-Release Versus Extended-Release Tablets--Clinical Implications Ann. Pharmacother., April 1, 2006; 40(4): 619 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Dodick Chronic Daily Headache N. Engl. J. Med., January 12, 2006; 354(2): 158 - 165. [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Wassef, D. E. Winkler, A. L. Roache, V. B. Abobo, L. M. Lopez, J. P. Averill, A. I. Mian, and J. E. Overall Lower Effectiveness of Divalproex Versus Valproic Acid in a Prospective, Quasi-Experimental Clinical Trial Involving 9,260 Psychiatric Admissions Am J Psychiatry, February 1, 2005; 162(2): 330 - 339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Silberstein, W. Neto, J. Schmitt, and D. Jacobs Topiramate in Migraine Prevention: Results of a Large Controlled Trial Arch Neurol, April 1, 2004; 61(4): 490 - 495. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Brandes, J. R. Saper, M. Diamond, J. R. Couch, D. W. Lewis, J. Schmitt, W. Neto, S. Schwabe, and D. Jacobs Topiramate for Migraine Prevention: A Randomized Controlled Trial JAMA, February 25, 2004; 291(8): 965 - 973. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
